Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

12,277 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
[Two cases of complex sleep apnea syndrome].
Yamada T, Arimoto T, Koyama Y, Masui A, Tamiya N, Hosogi S, Hiramatu A, Nakanishi M, Kohno Y, Ueda M, Iwasaki Y, Marunaka Y. Yamada T, et al. Nihon Kokyuki Gakkai Zasshi. 2009 Sep;47(9):793-7. Nihon Kokyuki Gakkai Zasshi. 2009. PMID: 19827583 Japanese.
Efficacy and Safety of Programmed Death-Ligand 1 Inhibitor Plus Platinum-Etoposide Chemotherapy in Patients With Extensive-Stage SCLC: A Prospective Observational Study.
Morimoto K, Yamada T, Takeda T, Shiotsu S, Date K, Harada T, Tamiya N, Chihara Y, Hiranuma O, Yamada T, Kanda H, Nakano T, Morimoto Y, Iwasaku M, Tokuda S, Takayama K. Morimoto K, et al. Among authors: yamada t. JTO Clin Res Rep. 2022 Jun 8;3(7):100353. doi: 10.1016/j.jtocrr.2022.100353. eCollection 2022 Jul. JTO Clin Res Rep. 2022. PMID: 35789793 Free PMC article.
Early Tumor Shrinkage as a Predictor of Favorable Treatment Outcomes in Patients With Extensive-Stage SCLC Who Received Programmed Cell Death-Ligand 1 Inhibitor Plus Platinum-Etoposide Chemotherapy: A Prospective Observational Study.
Ishida M, Morimoto K, Yamada T, Takeda T, Shiotsu S, Date K, Harada T, Tamiya N, Chihara Y, Takemura Y, Yamada T, Kanda H, Iwasaku M, Tokuda S, Kim YH, Takayama K. Ishida M, et al. Among authors: yamada t. JTO Clin Res Rep. 2023 Feb 28;4(4):100493. doi: 10.1016/j.jtocrr.2023.100493. eCollection 2023 Apr. JTO Clin Res Rep. 2023. PMID: 37025120 Free PMC article.
Prospective Observational Study Evaluating the Prognostic Value of the G8 Screening Tool for Extensive-Stage Small Cell Lung Cancer Patients Who Received Programmed Death-Ligand 1 Inhibitor plus Platinum-Etoposide Chemotherapy.
Morimoto K, Yamada T, Takeda T, Shiotsu S, Date K, Harada T, Tamiya N, Chihara Y, Takemura Y, Yamada T, Kanda H, Ishida M, Yoshimura A, Iwasaku M, Tokuda S, Kim YH, Takayama K. Morimoto K, et al. Among authors: yamada t. Drugs Aging. 2023 Jun;40(6):563-571. doi: 10.1007/s40266-023-01034-4. Epub 2023 May 5. Drugs Aging. 2023. PMID: 37145245
Prophylactic treatment of dacomitinib-induced skin toxicities in epidermal growth factor receptor-mutated non-small-cell lung cancer: A multicenter, Phase II trial.
Iwasaku M, Uchino J, Chibana K, Tanzawa S, Yamada T, Tobino K, Uchida Y, Kijima T, Nakatomi K, Izumi M, Tamiya N, Kimura H, Fujita M, Honda R, Takumi C, Yamada T, Kaneko Y, Kiyomi F, Takayama K. Iwasaku M, et al. Among authors: yamada t. Cancer Med. 2023 Jul;12(14):15117-15127. doi: 10.1002/cam4.6184. Epub 2023 Jun 3. Cancer Med. 2023. PMID: 37269194 Free PMC article. Clinical Trial.
First-Line Chemoimmunotherapy versus Sequential Platinum-Based Chemotherapy Followed by Immunotherapy in Patients with Non-Small Cell Lung Cancer with ≤49% Programmed Death-Ligand 1 Expression: A Real-World Multicenter Retrospective Study.
Tanimura K, Takeda T, Kataoka N, Yoshimura A, Nakanishi K, Yamanaka Y, Yoshioka H, Honda R, Uryu K, Fukui M, Chihara Y, Takei S, Kawachi H, Yamada T, Tamiya N, Okura N, Yamada T, Murai J, Shiotsu S, Kurata T, Takayama K. Tanimura K, et al. Among authors: yamada t. Cancers (Basel). 2023 Oct 14;15(20):4988. doi: 10.3390/cancers15204988. Cancers (Basel). 2023. PMID: 37894357 Free PMC article.
Impact of the response to platinum-based chemotherapy on the second-line immune checkpoint inhibitor monotherapy in non-small cell lung cancer with PD-L1 expression ≤49%: a multicenter retrospective study.
Yoshimura A, Takeda T, Kataoka N, Tanimura K, Fukui M, Chihara Y, Takei S, Kawachi H, Nakanishi K, Yamanaka Y, Tamiya N, Honda R, Okura N, Yamada T, Uryu K, Murai J, Shiotsu S, Yoshioka H, Yamada T, Kurata T, Takayama K. Yoshimura A, et al. Among authors: yamada t. Front Oncol. 2024 Jan 26;14:1303543. doi: 10.3389/fonc.2024.1303543. eCollection 2024. Front Oncol. 2024. PMID: 38344209 Free PMC article.
12,277 results
You have reached the last available page of results. Please see the User Guide for more information.